Search the Newsreel

DaVita Inc. Stock 12‑Month Price Target Raised to $230, Implies 1% Upside

Analysts have raised the 12-month average price target for DaVita Inc. (DVA) stock from $217.33 to $230, with individual forecasts ranging from $170 to $270 per share. This new target suggests a 1% potential upside based on the stock's closing price on August 4. …

Vitesse Energy Tightens 2026 Outlook After Strong Quarter

Vitesse Energy reported strong second-quarter 2026 results with a net income of $33.1 million and average production up 9% sequentially. The company reinforced its shareholder-return strategy by maintaining its fixed dividend and tightened its 2026 guidance, slightly narrowing production and oil mix ranges while …

Evercore ISI Adjusts Price Target on Revvity to $126 From $125, Maintains Outperform Rating

Evercore ISI has increased its price target for Revvity (RVTY) to $126 from $125, while reaffirming its "Outperform" rating on the stock. This adjustment reflects continued positive sentiment from the analyst firm regarding Revvity's financial prospects and market position. The update follows recent financial …

Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact

Ingevity Corporation has released its 2025 Sustainability Report, titled "A Decade of Performance, a Future of Possibility," which details how its advanced materials and technologies help customers achieve environmental goals. The report highlights the company's commitment to sustainability through products that reduce emissions, extend …

Revvity Inc reports results for the quarter ended June 30 - Earnings Summary

Revvity Inc has released its earnings summary for the quarter that ended on June 30. The article, provided by Refinitiv and distributed through TradingView, is an earnings report. Full access to the complete article and other news sources is available through a TradingView subscription.

Revvity (RVTY) Stock Premium Faces Pressure From Thin Margins

Revvity (RVTY) stock experienced a 3% dip despite exceeding Q2 earnings expectations, raising concerns about its high P/E ratio of 52.4x and recent squeeze in net profit margin to 8.2%. The article explores both the bullish arguments, such as organic growth in diagnostics and …

DaVita Inc (DVA) (Q2 2026) Earnings Call Highlights: Strong Volume Growth and Strategic ...

DaVita Inc. reported strong Q2 2026 results with adjusted operating income of $579 million and EPS of $4.02, driven by higher-than-expected treatment volume growth. The company reaffirmed its full-year guidance and continued share repurchases. While facing headwinds like declining revenue per treatment due to …

Is Vita Coco Company (COCO) Cheap After Strong Q2 And First Half 2026 Results?

Amundi Sells 32,858 Shares of Revvity Inc. $RVTY

Savita Oil Technologies reports record Q1FY27 revenue of ₹1,512.7 crore

DaVita (DVA) Stock Price Faces Margin Doubts After 17% Sell Off

Vital Farms (VITL) Reports Q2: Everything You Need To Know Ahead Of Earnings

Vital Farms (VITL), an egg and butter company, is scheduled to report its Q2 earnings this Thursday morning. The market anticipates a 10.8% year-on-year revenue decline, a reversal from the previous year's increase, and analysts have largely maintained their estimates. Despite Vital Farms' stock …

Ingevity (NYSE: NGVT) legal chief Ryan Fisher sells 2,709 shares

Ingevity's SVP, General Counsel & Secretary, Ryan C. Fisher, sold a total of 2,709 shares of company common stock on August 3, 2026. The sales were conducted in two separate open market transactions at prices of $73.76 and $73.67 per share, totaling approximately $200,000. …

DaVita Expands Access to Advanced Middle Molecule Clearance

DaVita is rapidly scaling access to advanced middle molecule clearance therapies like Expanded Hemodialysis (Expanded HD) and continuing hemodiafiltration (HDF) pilots to improve kidney care outcomes. This expansion is driven by the recent FDA approval of Nipro’s ELISIO-HX dialyzer, which allows for greater removal …

DaVita Inc. 2026: Revenue $3.55B, EPS $4.02— 10-Q Summary

DaVita Inc. reported strong financial results for the quarter ended 2026, with revenue reaching $3.55 billion and diluted EPS at $4.02, marking significant increases over the prior-year quarter. The growth was primarily driven by higher U.S. dialysis volumes and a substantial increase in ancillary …

DaVita's Profit Growth Prospects Boosted by Share Repurchases

DaVita's profit growth is expected to improve due to share repurchases, despite recent challenges from COVID-related mortality and labor pressures. The company, which specializes in services for end-stage renal disease patients, has a large network of dialysis clinics in the US and is expanding …

How Investors May Respond To TE Connectivity (TEL) Earnings Beat And Completion Of Long-Term Buyback

TE Connectivity (TEL) reported higher sales and net income in its past quarter and completed a long-running share repurchase program. This combination of stronger earnings per share and a reduced share count highlights the company's profit growth paired with sustained capital returns. The article …

Does Vita Coco (COCO) Have the Earnings Power to Justify Its Premium Valuation Narrative?

[DVA Q2 2026 Earnings Call] DaVita to Roll Out Expanded Dialyzers Across Network, Lifts Volume Target to 50-75 Basis Points

DaVita reported Q2 2026 adjusted operating income of $579 million and adjusted EPS of $4.02, meeting expectations, with treatment volume growth accelerating to 56 basis points due to improved mortality. The company announced plans to broadly deploy newly FDA-approved expanded hemodialysis dialyzers following a …

DaVita falls despite top and bottom line beats

[Q2 second quarter business report infographic data] cagkansayin * DaVita (DVA [https://seekingalpha.com/symbol/DVA]) is down ~7% in after-hours trading Tuesday despite releasing Q2 financial results that beat [https://seekingalpha.com/news/4625305-davita-non-gaap-eps-of-4_02-beats-by-0_14-revenue-of-3_55b-beats-by-60m] on both lines and maintaining its 2026 guidance. * Adjusted diluted EPS for the year is seen …

Vitesse Energy Inc (VTS) (Q2 2026) Earnings Call Highlights: Record Production and Durable ... By GuruFocus

Vitesse Energy Inc (VTS) reported strong Q2 2026 results with record production averaging 17,354 BOE per day, a 9% sequential increase, and declared its 15th consecutive quarterly dividend. The company highlighted a strong balance sheet, effective hedging strategies extending into 2029, and improved capital …

Earnings call transcript: DaVita beats Q2 2026 estimates but shares fall

DaVita Inc. reported its Q2 2026 earnings, highlighting volume growth driven by improved patient mortality and better management of phosphate levels, though revenue per treatment declined due to lower commercial mix and binder revenue. The company is pivoting towards expanded hemodialysis technology and reconfirmed …

Vitesse Energy, Inc. (NYSE:VTS) Receives Average Recommendation of "Hold" from Analysts

Vitesse Energy, Inc. (NYSE:VTS) has received an average "Hold" recommendation from analysts, with a mixed outlook including buy, hold, and sell ratings. Despite trading near its 1-year low, the company announced a quarterly dividend yielding 11.3% annually. Insider and institutional ownership are significant, and …

DaVita Slides as Solid Q2 Results Fail to Lift Full-Year Outlook

DaVita (DVA) stock fell 9.1% despite solid second-quarter results, likely due to investors expecting a full-year guidance raise that did not materialize. The company reported increased revenue, earnings, and cash flow for Q2 2026 but maintained its previously issued full-year guidance. Factors such as …

DaVita (NYSE:DVA) Beats Q2 CY2026 Sales Expectations But Stock Drops

DaVita (NYSE:DVA) reported better-than-expected Q2 CY2026 revenue of $3.55 billion, a 5.2% year-on-year increase, and an adjusted EPS of $4.02, beating analyst estimates. Despite these positive results, the company's stock dropped by 9.8% to $210.75 immediately after the announcement, partly due to full-year EPS …

DaVita earnings beat by $0.18, revenue topped estimates

DaVita (NYSE: DVA) reported strong second-quarter results, beating analyst estimates with an EPS of $4.02 and revenue of $3.55 billion. The company also provided a positive outlook for fiscal year 2026, with an EPS guidance of $14.10-$15.20. DaVita's stock has shown significant growth, up …

No-Moat Revvity Sees Solid First-Half Performance With Momentum Likely to Continue

Revvity, formerly PerkinElmer, has demonstrated solid first-half performance in 2026, with strong earnings boosting its outlook. The company, which rebranded after divesting its applied, food, and enterprise services business, now focuses on diagnostics and life sciences. This positive momentum is expected to continue, driven …

DaVita reports Q2 2026 revenue of $3.55B, net i...

DaVita Inc. announced strong Q2 2026 results with consolidated revenues of $3.554 billion and net income attributable to DaVita of $265 million, an increase from $199 million in Q2 2025. The company's operating income rose to $579 million due to increased dialysis treatments and …

[10-Q] DAVITA INC. Quarterly Earnings Report

DaVita Inc. has filed its unaudited quarterly report (Form 10-Q) for the quarter ended June 30, 2026. Key financial highlights include share repurchases, an increase in Term Loan B-2 principal, and the recent acquisition of a minority interest in Elara Caring. The report details …

Earnings Flash (DVA) DaVita Inc. Reports Q2 Revenue $3.55B, vs. FactSet Est of $3.50B

DaVita Inc. (DVA) reported Q2 revenue of $3.55 billion, surpassing FactSet's estimate of $3.50 billion. The company also announced an adjusted EPS of $4.02 per share for Q2, exceeding the FactSet estimate of $3.88. Additionally, DaVita expects its full-year 2026 adjusted EPS to range …

Earnings Flash (DVA) DaVita Inc. Posts Q2 Adjusted EPS $4.02 per Share, vs. FactSet Est of $3.88

DaVita Inc. (DVA) announced Q2 adjusted earnings per share of $4.02, surpassing the FactSet estimate of $3.88. The company also reported Q2 revenue of $3.55 billion, exceeding the FactSet estimate of $3.50 billion. DaVita expects its full-year 2026 adjusted EPS to be in the …

DaVita reports Q2 2026: Revenue $3.554B, Operating income $579M, Diluted EPS $4.02

DaVita (DVA) reported its second-quarter 2026 financial results, with consolidated revenues reaching $3.554 billion, operating income at $579 million, and diluted earnings per share of $4.02. The company generated $490 million in operating cash flow and $256 million in free cash flow, while also …

DaVita Inc. 2nd Quarter 2026 Results

DENVER, Aug. 4, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2026. "Thanks to the outstanding efforts of our teammates, we had another positive quarter for both patient outcomes and financial results," said Javier …

Revvity raises annual profit, revenue forecasts on strong diagnostics demand

Medical equipment maker Revvity has increased its annual profit and revenue forecasts after exceeding Wall Street expectations for the second quarter. This improvement is attributed to stronger demand for its drug-development tools and diagnostic testing products, with AI-related work contributing to incremental demand. Despite …

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity, Inc. (RVTY) reported strong second-quarter 2026 results, with adjusted EPS of $1.41 and revenues of $729.7 million, both surpassing analyst estimates, driven by strength in its Diagnostics segment. The company also raised its full-year 2026 pro forma outlook for revenues and adjusted EPS. …

DaVita earnings on deck as dialysis giant eyes value-based growth

DaVita HealthCare Partners Inc. is preparing to report its second-quarter earnings, with analysts anticipating strong performance driven by its shift towards value-based care. The company's Integrated Kidney Care platform and operational efficiencies, including an AI-enabled scheduling tool, are key areas of focus for investors. …